Biogen director receives 1,505-share equity grant

Mantas Jesus B reported acquisition or exercise transactions in this Form 4 filing.

Accepted by SEC EDGAR 06/11/2026 - 05:44 PM EDT Learn about SEC filing dates

Rhea-AI Filing Summary

Mantas Jesus B reported acquisition or exercise transactions in this Form 4 filing.

BIOGEN INC. director Jesus B. Mantas reported an equity award of 1,505 shares of Common Stock, received as a grant rather than a market purchase. Following this award, his direct ownership increased to 11,263 shares.

The filing notes that the associated restricted stock units vest on the earlier of the company’s next annual meeting or the anniversary of the June 9, 2026 grant date, tying the award to continued board service over that period.

Insider Trade Summary

Grant/Award: 1,505 shares

Grant/Award 1 txn

Insider Mantas Jesus B

Role Director

Type	Security	Shares	Price	Value
Grant/Award	Common Stock	1,505	$0.00	$0.00

Holdings After Transaction: Common Stock — 11,263 shares (Direct)

Holdings Before and After: Common Stock, 9,758 to 11,263 shares (Direct)

Footnotes (1)

1. F1. The restricted stock units vest on the earlier of (i) the next annual meeting or (ii) the anniversary of the date of grant of June 9, 2026.

Key Figures

Shares granted: 1,505 shares Post-transaction holdings: 11,263 shares Grant price per share: $0.0000 +1 more

4 metrics

Shares granted 1,505 shares Equity grant to director Jesus B. Mantas

Post-transaction holdings 11,263 shares Direct Common Stock owned after grant

Grant price per share $0.0000 Reported transaction price per share for award

Vesting latest date June 9, 2026 RSUs vest by earlier of next annual meeting or this date

Key Terms

restricted stock units, Common Stock, Grant, award, or other acquisition, annual meeting

4 terms

restricted stock units financial

"The restricted stock units vest on the earlier of (i) the next annual meeting or (ii) the anniversary of the date of grant of June 9, 2026."

Restricted stock units are a type of company reward where employees are promised shares of stock, but they only fully own these shares after meeting certain conditions, like staying with the company for a set time. They matter because they can become valuable assets and are often used to motivate employees to help the company succeed.

Common Stock financial

"security_title: "Common Stock" and an award of 1,505 shares was reported."

Common stock represents ownership shares in a company, giving investors a stake in its success and a say in important decisions through voting rights. It is the most common type of stock traded on markets and can provide income through dividends, as well as potential for value growth. For investors, holding common stock means sharing in the company’s profits and risks.

Grant, award, or other acquisition financial

"transaction_code_description: "Grant, award, or other acquisition" describes the nature of the transaction."

annual meeting financial

"The restricted stock units vest on the earlier of (i) the next annual meeting or (ii) the anniversary of the date of grant of June 9, 2026."

A company's annual meeting is a yearly gathering where owners (shareholders) and the board review performance, ask questions, and vote on key matters like electing directors, approving auditor choices, and sometimes setting pay or dividend policies. For investors it matters because decisions made and votes cast can change who runs the company, influence strategy and payouts, and affect the value or direction of their investment—similar to a homeowners’ meeting where rules and leaders that shape your property’s value are decided.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did Biogen (BIIB) director Jesus B. Mantas report in this Form 4?

Jesus B. Mantas reported receiving an award of 1,505 shares of Biogen Common Stock. This was a grant, not an open-market purchase, and increased his direct holdings to 11,263 shares, reflecting routine equity-based director compensation at the company.

How many Biogen (BIIB) shares does Jesus B. Mantas own after this grant?

After the reported equity grant, Jesus B. Mantas directly owns 11,263 Biogen Common Stock shares. This total includes the newly awarded 1,505-share grant disclosed in the Form 4, providing a snapshot of his direct equity stake following the transaction.

What type of transaction is reported for Biogen (BIIB) director Mantas?

The transaction is classified as a grant or award acquisition of Common Stock, coded “A” on Form 4. It reflects restricted stock units granted as part of compensation, with no cash purchase price and no shares sold in this disclosure.

When do the Biogen (BIIB) restricted stock units granted to Mantas vest?

The restricted stock units granted to Jesus B. Mantas vest on the earlier of Biogen’s next annual meeting or the June 9, 2026 grant anniversary. This schedule links the award’s vesting to ongoing board service over that period, as described in the filing footnote.

Does this Biogen (BIIB) Form 4 show any stock sales by Jesus B. Mantas?

The Form 4 does not report any stock sales by Jesus B. Mantas. It shows only an acquisition coded as a grant, adding 1,505 shares of Common Stock to his direct holdings and bringing his post-transaction position to 11,263 shares.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Mantas Jesus B

(Last) (First) (Middle)

BIOGEN INC.

225 BINNEY ST.

(Street)

CAMBRIDGE MASSACHUSETTS 02142

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
BIOGEN INC. [ BIIB ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
06/09/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	06/09/2026		A		1,505(1)	A	$0	11,263	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. The restricted stock units vest on the earlier of (i) the next annual meeting or (ii) the anniversary of the date of grant of June 9, 2026.

	/s/ Wendell Taylor, Attorney in Fact for Jesus B. Mantas	06/11/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)